1
|
Buffet C, Hecale-Perlemoine K, Bricaire L, Dumont F, Baudry C, Tissier F, Bertherat J, Cochand-Priollet B, Raffin-Sanson ML, Cormier F, Groussin L. DUSP5 and DUSP6, two ERK specific phosphatases, are markers of a higher MAPK signaling activation in BRAF mutated thyroid cancers. PLoS One 2017; 12:e0184861. [PMID: 28910386 PMCID: PMC5599027 DOI: 10.1371/journal.pone.0184861] [Citation(s) in RCA: 35] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/09/2016] [Accepted: 09/03/2017] [Indexed: 02/05/2023] Open
Abstract
Background Molecular alterations of the MAPK pathway are frequently observed in papillary thyroid carcinomas (PTCs). It leads to a constitutive activation of the signalling pathway through an increase in MEK and ERK phosphorylation. ERK is negatively feedback-regulated by Dual Specificity Phosphatases (DUSPs), especially two ERK-specific DUSPs, DUSP5 (nuclear) and DUSP6 (cytosolic). These negative MAPK regulators may play a role in thyroid carcinogenesis. Methods MAPK pathway activation was analyzed in 11 human thyroid cancer cell lines. Both phosphatases were studied in three PCCL3 rat thyroid cell lines that express doxycycline inducible PTC oncogenes (RET/PTC3, H-RASV12 or BRAFV600E). Expression levels of DUSP5 and DUSP6 were quantified in 39 human PTCs. The functional role of DUSP5 and DUSP6 was investigated through their silencing in two human BRAFV600E carcinoma cell lines. Results BRAFV600E human thyroid cancer cell lines expressed higher phospho-MEK levels but not higher phospho-ERK levels. DUSP5 and DUSP6 are specifically induced by the MEK-ERK pathway in the three PTC oncogenes inducible thyroid cell lines. This negative feedback loop explains the tight regulation of p-ERK levels. DUSP5 and DUSP6 mRNA are overexpressed in human PTCs, especially in BRAFV600E mutated PTCs. DUSP5 and/or DUSP6 siRNA inactivation did not affect proliferation in two BRAFV600E mutated cell lines, which may be explained by a compensatory increase in other phosphatases. In the light of this, we observed a marked DUSP6 upregulation upon DUSP5 inactivation. Despite this, DUSP5 and DUSP6 positively control cell migration and invasion. Conclusions Our results are in favor of a stronger activation of the MAPK pathway in BRAFV600E PTCs. DUSP5 and DUSP6 have pro-tumorigenic properties in two BRAFV600E PTC cell line models.
Collapse
Affiliation(s)
- Camille Buffet
- INSERM, U1016, Institut Cochin, Paris, France
- CNRS, UMR8104, Paris, France
- Université Paris Descartes, Sorbonne Paris Cité, France
- * E-mail:
| | - Karine Hecale-Perlemoine
- INSERM, U1016, Institut Cochin, Paris, France
- CNRS, UMR8104, Paris, France
- Université Paris Descartes, Sorbonne Paris Cité, France
| | - Léopoldine Bricaire
- INSERM, U1016, Institut Cochin, Paris, France
- CNRS, UMR8104, Paris, France
- Université Paris Descartes, Sorbonne Paris Cité, France
| | - Florent Dumont
- INSERM, U1016, Institut Cochin, Paris, France
- CNRS, UMR8104, Paris, France
- Université Paris Descartes, Sorbonne Paris Cité, France
| | - Camille Baudry
- INSERM, U1016, Institut Cochin, Paris, France
- CNRS, UMR8104, Paris, France
- Université Paris Descartes, Sorbonne Paris Cité, France
| | - Frédérique Tissier
- INSERM, U1016, Institut Cochin, Paris, France
- CNRS, UMR8104, Paris, France
- Université Paris Descartes, Sorbonne Paris Cité, France
- Department of Pathology, Pitié-Salpêtrière Hospital, Paris, France
| | - Jérôme Bertherat
- INSERM, U1016, Institut Cochin, Paris, France
- CNRS, UMR8104, Paris, France
- Université Paris Descartes, Sorbonne Paris Cité, France
- Department of Endocrinology, Cochin Hospital, Paris, France
| | | | | | - Françoise Cormier
- INSERM, U1016, Institut Cochin, Paris, France
- CNRS, UMR8104, Paris, France
- Université Paris Descartes, Sorbonne Paris Cité, France
| | - Lionel Groussin
- INSERM, U1016, Institut Cochin, Paris, France
- CNRS, UMR8104, Paris, France
- Université Paris Descartes, Sorbonne Paris Cité, France
- Department of Endocrinology, Cochin Hospital, Paris, France
| |
Collapse
|
3
|
Yuan Y, Yan L, Wu QQ, Zhou H, Jin YG, Bian ZY, Deng W, Yang Z, Shen DF, Zeng XF, Wang SS, Li H, Tang QZ. Mnk1 (Mitogen-Activated Protein Kinase-Interacting Kinase 1) Deficiency Aggravates Cardiac Remodeling in Mice. Hypertension 2016; 68:1393-1399. [PMID: 27698061 DOI: 10.1161/hypertensionaha.116.07906] [Citation(s) in RCA: 29] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/26/2016] [Revised: 06/03/2016] [Accepted: 09/12/2016] [Indexed: 01/19/2023]
Abstract
Identifying the key factor involved in cardiac remodeling is critically important for developing novel strategies to protect against heart failure. Here, the role of Mnk1 (mitogen-activated protein kinase-interacting kinase 1) in cardiac remodeling was clarified. Cardiac remodeling was induced by transverse aortic constriction in Mnk1-knockout mice and their wild-type control mice. After 4 weeks of transverse aortic constriction, Mnk1-knockout mice developed exaggerated cardiac hypertrophy, fibrosis, dysfunction, and cardiomyocyte apoptosis and showed increased ERK1/2 (extracellular signal-regulated kinase 1/2) activation along with reduced sprouty2 expression. In line with the in vivo studies, Mnk1 knockdown by Mnk1 siRNA transfection induced exaggerated angiotensin II-induced cardiomyocyte hypertrophy in neonatal rat ventricular myocytes (NRVMs). Moreover, adenovirus-mediated overexpression of Mnk1 in NRVMs protected cardiomyocytes from angiotensin II-induced hypertrophy. In addition, overexpression of sprouty2 rescued NRVMs with Mnk1 knockdown from angiotensin II-induced hypertrophy. In accordance with the in vivo studies, as compared with the control group, Mnk1 knockdown led to hyperphosphorylation of ERK1/2 and suppression of the sprouty2 expression in angiotensin II-treated NRVMs; furthermore, Mnk1 overexpression led to hypophosphorylation of ERK1/2 in angiotensin II-treated NRVMs. In addition, sprouty2 overexpression suppressed the activation of ERK1/2 in angiotensin II-treated NRVMs with Mnk1 knockdown. Impressively, MnK1-knockout mice with overexpression of sprouty2 exhibited signs of a blunted cardiac hypertrophic response. Mnk1 likely carries out a suppressive function in cardiac hypertrophy via regulating the sprouty2/ERK1/2 pathway. It implicates Mnk1 in the development of cardiac remodeling.
Collapse
Affiliation(s)
- Yuan Yuan
- From the Department of Cardiology, Renmin Hospital of Wuhan University, China (Y.Y., L.Y., Q.-Q.W., H.Z., Y.-G.J., Z.-Y.B., W.D., Z.Y., D.-F.S., H.L., Q.-Z.T.); and Cardiovascular Research Institute of Wuhan University, China (Y.Y., L.Y., Q.-Q.W., H.Z., Y.-G.J., Z.-Y.B., W.D., Z.Y., D.-F.S., X.-F.Z., S.-S.W., H.L., Q.-Z.T.)
| | - Ling Yan
- From the Department of Cardiology, Renmin Hospital of Wuhan University, China (Y.Y., L.Y., Q.-Q.W., H.Z., Y.-G.J., Z.-Y.B., W.D., Z.Y., D.-F.S., H.L., Q.-Z.T.); and Cardiovascular Research Institute of Wuhan University, China (Y.Y., L.Y., Q.-Q.W., H.Z., Y.-G.J., Z.-Y.B., W.D., Z.Y., D.-F.S., X.-F.Z., S.-S.W., H.L., Q.-Z.T.)
| | - Qing-Qing Wu
- From the Department of Cardiology, Renmin Hospital of Wuhan University, China (Y.Y., L.Y., Q.-Q.W., H.Z., Y.-G.J., Z.-Y.B., W.D., Z.Y., D.-F.S., H.L., Q.-Z.T.); and Cardiovascular Research Institute of Wuhan University, China (Y.Y., L.Y., Q.-Q.W., H.Z., Y.-G.J., Z.-Y.B., W.D., Z.Y., D.-F.S., X.-F.Z., S.-S.W., H.L., Q.-Z.T.)
| | - Heng Zhou
- From the Department of Cardiology, Renmin Hospital of Wuhan University, China (Y.Y., L.Y., Q.-Q.W., H.Z., Y.-G.J., Z.-Y.B., W.D., Z.Y., D.-F.S., H.L., Q.-Z.T.); and Cardiovascular Research Institute of Wuhan University, China (Y.Y., L.Y., Q.-Q.W., H.Z., Y.-G.J., Z.-Y.B., W.D., Z.Y., D.-F.S., X.-F.Z., S.-S.W., H.L., Q.-Z.T.)
| | - Ya-Ge Jin
- From the Department of Cardiology, Renmin Hospital of Wuhan University, China (Y.Y., L.Y., Q.-Q.W., H.Z., Y.-G.J., Z.-Y.B., W.D., Z.Y., D.-F.S., H.L., Q.-Z.T.); and Cardiovascular Research Institute of Wuhan University, China (Y.Y., L.Y., Q.-Q.W., H.Z., Y.-G.J., Z.-Y.B., W.D., Z.Y., D.-F.S., X.-F.Z., S.-S.W., H.L., Q.-Z.T.)
| | - Zhou-Yan Bian
- From the Department of Cardiology, Renmin Hospital of Wuhan University, China (Y.Y., L.Y., Q.-Q.W., H.Z., Y.-G.J., Z.-Y.B., W.D., Z.Y., D.-F.S., H.L., Q.-Z.T.); and Cardiovascular Research Institute of Wuhan University, China (Y.Y., L.Y., Q.-Q.W., H.Z., Y.-G.J., Z.-Y.B., W.D., Z.Y., D.-F.S., X.-F.Z., S.-S.W., H.L., Q.-Z.T.)
| | - Wei Deng
- From the Department of Cardiology, Renmin Hospital of Wuhan University, China (Y.Y., L.Y., Q.-Q.W., H.Z., Y.-G.J., Z.-Y.B., W.D., Z.Y., D.-F.S., H.L., Q.-Z.T.); and Cardiovascular Research Institute of Wuhan University, China (Y.Y., L.Y., Q.-Q.W., H.Z., Y.-G.J., Z.-Y.B., W.D., Z.Y., D.-F.S., X.-F.Z., S.-S.W., H.L., Q.-Z.T.)
| | - Zheng Yang
- From the Department of Cardiology, Renmin Hospital of Wuhan University, China (Y.Y., L.Y., Q.-Q.W., H.Z., Y.-G.J., Z.-Y.B., W.D., Z.Y., D.-F.S., H.L., Q.-Z.T.); and Cardiovascular Research Institute of Wuhan University, China (Y.Y., L.Y., Q.-Q.W., H.Z., Y.-G.J., Z.-Y.B., W.D., Z.Y., D.-F.S., X.-F.Z., S.-S.W., H.L., Q.-Z.T.)
| | - Di-Fei Shen
- From the Department of Cardiology, Renmin Hospital of Wuhan University, China (Y.Y., L.Y., Q.-Q.W., H.Z., Y.-G.J., Z.-Y.B., W.D., Z.Y., D.-F.S., H.L., Q.-Z.T.); and Cardiovascular Research Institute of Wuhan University, China (Y.Y., L.Y., Q.-Q.W., H.Z., Y.-G.J., Z.-Y.B., W.D., Z.Y., D.-F.S., X.-F.Z., S.-S.W., H.L., Q.-Z.T.)
| | - Xiao-Feng Zeng
- From the Department of Cardiology, Renmin Hospital of Wuhan University, China (Y.Y., L.Y., Q.-Q.W., H.Z., Y.-G.J., Z.-Y.B., W.D., Z.Y., D.-F.S., H.L., Q.-Z.T.); and Cardiovascular Research Institute of Wuhan University, China (Y.Y., L.Y., Q.-Q.W., H.Z., Y.-G.J., Z.-Y.B., W.D., Z.Y., D.-F.S., X.-F.Z., S.-S.W., H.L., Q.-Z.T.)
| | - Sha-Sha Wang
- From the Department of Cardiology, Renmin Hospital of Wuhan University, China (Y.Y., L.Y., Q.-Q.W., H.Z., Y.-G.J., Z.-Y.B., W.D., Z.Y., D.-F.S., H.L., Q.-Z.T.); and Cardiovascular Research Institute of Wuhan University, China (Y.Y., L.Y., Q.-Q.W., H.Z., Y.-G.J., Z.-Y.B., W.D., Z.Y., D.-F.S., X.-F.Z., S.-S.W., H.L., Q.-Z.T.)
| | - Hongliang Li
- From the Department of Cardiology, Renmin Hospital of Wuhan University, China (Y.Y., L.Y., Q.-Q.W., H.Z., Y.-G.J., Z.-Y.B., W.D., Z.Y., D.-F.S., H.L., Q.-Z.T.); and Cardiovascular Research Institute of Wuhan University, China (Y.Y., L.Y., Q.-Q.W., H.Z., Y.-G.J., Z.-Y.B., W.D., Z.Y., D.-F.S., X.-F.Z., S.-S.W., H.L., Q.-Z.T.)
| | - Qi-Zhu Tang
- From the Department of Cardiology, Renmin Hospital of Wuhan University, China (Y.Y., L.Y., Q.-Q.W., H.Z., Y.-G.J., Z.-Y.B., W.D., Z.Y., D.-F.S., H.L., Q.-Z.T.); and Cardiovascular Research Institute of Wuhan University, China (Y.Y., L.Y., Q.-Q.W., H.Z., Y.-G.J., Z.-Y.B., W.D., Z.Y., D.-F.S., X.-F.Z., S.-S.W., H.L., Q.-Z.T.).
| |
Collapse
|
6
|
Milewska M, Romano D, Herrero A, Guerriero ML, Birtwistle M, Quehenberger F, Hatzl S, Kholodenko BN, Segatto O, Kolch W, Zebisch A. Mitogen-Inducible Gene-6 Mediates Feedback Inhibition from Mutated BRAF towards the Epidermal Growth Factor Receptor and Thereby Limits Malignant Transformation. PLoS One 2015; 10:e0129859. [PMID: 26065894 PMCID: PMC4466796 DOI: 10.1371/journal.pone.0129859] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/18/2014] [Accepted: 05/13/2015] [Indexed: 01/15/2023] Open
Abstract
BRAF functions in the RAS-extracellular signal-regulated kinase (ERK) signaling cascade. Activation of this pathway is necessary to mediate the transforming potential of oncogenic BRAF, however, it may also cause a negative feedback that inhibits the epidermal growth factor receptor (EGFR). Mitogen-inducible gene-6 (MIG-6) is a potent inhibitor of the EGFR and has been demonstrated to function as a tumor suppressor. As MIG-6 can be induced via RAS-ERK signaling, we investigated its potential involvement in this negative regulatory loop. Focus formation assays were performed and demonstrated that MIG-6 significantly reduces malignant transformation induced by oncogenic BRAF. Although this genetic interaction was mirrored by a physical interaction between MIG-6 and BRAF, we did not observe a direct regulation of BRAF kinase activity by MIG-6. Interestingly, a selective chemical EGFR inhibitor suppressed transformation to a similar degree as MIG-6, whereas combining these approaches had no synergistic effect. By analyzing a range of BRAF mutated and wildtype cell line models, we could show that BRAF V600E causes a strong upregulation of MIG-6, which was mediated at the transcriptional level via the RAS-ERK pathway and resulted in downregulation of EGFR activation. This feedback loop is operational in tumors, as shown by the analysis of almost 400 patients with papillary thyroid cancer (PTC). Presence of BRAF V600E correlated with increased MIG-6 expression on the one hand, and with inactivation of the EGFR and of PI3K/AKT signaling on the other hand. Importantly, we also observed a more aggressive disease phenotype when BRAF V600E coexisted with low MIG-6 expression. Finally, analysis of methylation data was performed and revealed that higher methylation of MIG-6 correlated to its decreased expression. Taken together, we demonstrate that MIG-6 efficiently reduces cellular transformation driven by oncogenic BRAF by orchestrating a negative feedback circuit directed towards the EGFR.
Collapse
Affiliation(s)
| | - David Romano
- Systems Biology Ireland, University College Dublin, Dublin, Ireland
| | - Ana Herrero
- Systems Biology Ireland, University College Dublin, Dublin, Ireland
| | | | - Marc Birtwistle
- Icahn School of Medicine at Mount Sinai, New York, New York, United States of America
| | - Franz Quehenberger
- Institute of Medical Informatics, Statistics and Documentation, Medical University of Graz, Graz, Austria
| | - Stefan Hatzl
- Division of Hematology, Medical University of Graz, Graz, Austria
| | - Boris N. Kholodenko
- Systems Biology Ireland, University College Dublin, Dublin, Ireland
- Conway Institute of Biomolecular & Biomedical Research, University College Dublin, Dublin, Ireland
- School of Medicine and Medical Science, University College Dublin, Dublin, Ireland
| | - Oreste Segatto
- Laboratory of Immunology, Regina Elena Cancer Institute, Rome, Italy
| | - Walter Kolch
- Systems Biology Ireland, University College Dublin, Dublin, Ireland
- Conway Institute of Biomolecular & Biomedical Research, University College Dublin, Dublin, Ireland
- School of Medicine and Medical Science, University College Dublin, Dublin, Ireland
| | - Armin Zebisch
- Division of Hematology, Medical University of Graz, Graz, Austria
- * E-mail:
| |
Collapse
|